Local and systemic reactions occurring during immunotherapy: An epidemiological evaluation and a prospective safety-monitoring study

Immunopharmacology and Immunotoxicology

Volumn 30, Issue 1, 2008, Pages 153-161

  Ventura, M T ^a,c   Giuliano, G ^a   Buquicchio, R ^a   Accettura, F ^a   Carbonara, M ^b  

^a UNIVERSITY OF BARI   (Italy)

^b Italian Statistical Institute   (Italy)

^c POLICLINICO   (Italy)

Author keywords

Local Reactions; Risk Factors; Specific Immunotherapy; Systemic Reactions

Indexed keywords

ALLERGEN; IMMUNOMODULATING AGENT;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ARTICLE; ASTHENIA; ASTHMA; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DERMATOPHAGOIDES; DRUG SAFETY; DRUG USE; EXERCISE; FEMALE; FEVER; FOLLOW UP; FOOD INTAKE; GENDER; HEADACHE; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOTHERAPY; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PARIETARIA; PATIENT MONITORING; PATIENT SAFETY; PHYSICAL ACTIVITY; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; REPIRATORY DIFFICULTY; RHINITIS; SCALP PRURITUS; STRESS; SUN EXPOSURE; SYMPTOM; THROAT TIGHTNESS; URTICARIA;

ADOLESCENT; ADULT; AGED; ANTIGENS; CHILD; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYPERSENSITIVITY; HYPERSENSITIVITY, IMMEDIATE; ITALY; MALE; MIDDLE AGED; RISK FACTORS;

DERMATOPHAGOIDES; HEXAPODA; PARIETARIA;

EID: 39749090142     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970701620008     Document Type: Article

References (24)

1. Creticos, P.S. The consideration of immunotherapy in the treatment of allergic asthma. J. Allergy Clin. Immunol. 2000, 105, S 559-574.
2. Van Cauwenberge, P.; Bachert, C.; Passalacqua G.; Bousquet, J.; Canonica G.W.; Durham S.R., et al. Consensus statement on the treatment of allergic rhinitis. Allergy. 2000, 55, 116-134.
3. WHO Position Paper (Bousquet, J.; Kathaev, N.; van Cauwenberge, P.; eds.). Allergic rhinitis and its impact on asthma (ARIA). J. Allergy Clin. Immunol. 2001, 108, 147-334.
4. Winther, L.; Malling, H.J.; Moseholm, L.; Mosbech, H. Allergen-specific immunotherapy in birch- and grass-pollen allergic rhinitis. Efficacy estimated by a model reducing the bias of annual differences in pollen count. Allergy. 2000, 55, 818-826.
5. Winther, L.; Malling, H.J.; Mosbech, H. Allergen-specific immunotherapy in birch- and grass-pollen allergic rhinitis. II. Side-effects. Allergy. 2000, 55, 827-835.
6. Committee on Safety of Medicines. Desensitizing vaccines. Brit. Med. J. 1986, 293, 948.
7. Malling, H.; Week, B. Immunotherapy. Position Paper of the European Academy of Allergy and Clinical Immunology. Allergy. 1993, 48 suppl 14, 9-35.
8. Stewart, G.D.; Lockey, R.F. Systemic reactions from allergen immunotherapy. J. Allergy Clin. Immunol. 1988, 90, 567-578.
9. Malling, H.; Weeke, B. Immunotherapy. Position Paper of the European Academy of Allergy and Clinical Immunology. Allergy, 1993, 48, Supp 14, 9-35.
10. Branco Ferreira, M., Spinola Santos, A., Pereira Santos, M.C., Palma Carlos, M.L., Pereira Barbosa, M.A., Palma Carlos, A.G. Efficacy and safety of specific immunotherapy with a modified mite extract. Allergol. Immunopathol. (Madr). 2005, 33(2), 80-85.
11. Moreno, C., Cuesta-Herranz, J., Fernandez-Tavora, L., Alvarez-Cuesta, E.; Immunotherapy Committee, Sociedad Espanola de Alergologia e Inmunologia Clinica. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin. Exp. Allergy. 2004, 34(4), 527-531.
12. Williams, A.P., Krishna, M.T., Frew, A.J. The safety of immunotherapy. Clin. Exp. Allergy. 2004 Apr., 34(4), 513-514.
13. Didier, A. The development of sublingual desensitization. Rev. Prat. 2005, Jun, 30, 55(12), 1334.
14. Reider, N. Sublingual immunotherapy for allergic rhinoconjunctivitis-the seeming and the real. Int. Arch. Allergy Immunol. 2005, 137(3), 181-186.
15. Riechelmann, H. Immunotherapy with allergen extracts for allergic rhinitis. HNO. 2005, Jun, 53(6), 517-520, 522-526, 528-530.
16. Can, D., Demir, E., Tanac, R., Gulen, F., Yenigun, A. Immediate adverse reactions to immunotherapy. J. Invest. Allergol. Clin. Immunol. 2003, 13(3): 177-180.
17. Gammeri, E., Arena, A., D'Anneo, R., La Grutta, S. Safety and tolerability of ultra-Rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol. Immunopathol. (Madr). 2005, 33(3), 142-144.
18. Nelson, H.S. Advances in upper airway diseases and allergen immunotherapy. J. Allergy Clin. Immunol. 2005, Apr, 115(4), 676-684.
19. Rossi, R.E., Monasterolo, G., Coco, G., Operti, D. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis. Int. Arch. Allergy Immunol. 2005, 138(2), 105-110.
20. Platts-Mills, T.A.E.; Mueller, G.A.; Wheatley, L.M. Future directions for allergen immunotherapy. J. Allergy Clin. Immunol. 1998, 102, 335-343.
21. Rogala, B. Risk and safety of immunotherapy. Allergy, 1998, 53, 473-476. 22.
22. Malling, H. Allergen-specific immunotherapy. Present state and directions for the future. Allergy, 1999. 54, 30-33.
23. Bousquet, J.; Michel, F.B. Safety consideration in assessing the role of immunotherapy in Allergic disorders. Drug Safety, 1994, 10, 5.
24. Bousquet, J.; Hejjaoui, A.; Michel, F.B. Specific Immunotherapy in asthma. J. Allergy Clin. Immunol. 1990, 86, 292-305.